Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
63%
Phase II Study
48%
Phase I Study
48%
Chemotherapy
39%
Docetaxel
33%
Maximum Tolerated Dose
30%
Lung Cancer
29%
Confidence Interval
28%
Small Cell Lung Cancer
27%
Erlotinib
23%
Temsirolimus
23%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
23%
Dose-limiting Toxicity
21%
Carboplatin-paclitaxel
21%
Carboplatin
20%
Progression-free Survival
20%
Platinum-based Chemotherapy
20%
Stable Disease
20%
Phase II Trial
20%
Solid Tumors
19%
Irinotecan
18%
Platinum-based
18%
Overall Survival
17%
Phase I Trial
17%
Epidermal Growth Factor Receptor
17%
Dose Level
15%
Women in Medicine
15%
Advanced Solid Malignancies
15%
Carfilzomib
15%
Pegylated Liposomal Doxorubicin
15%
Bexarotene
15%
Adjuvant Chemotherapy
15%
Randomized Phase II Trial
15%
Sunitinib
15%
Placebo-controlled
15%
Hazard Ratio
14%
First-line Therapy
13%
4-cycle
12%
Neutropenia
11%
Placebo
11%
Leukemia
11%
Thrombocytopenia
11%
Clinical Trials
10%
Platelet-derived Growth Factor Receptor (PDGFR)
10%
Combination Chemotherapy
10%
Advanced Stage
10%
Newly Diagnosed
10%
Solid Malignancies
9%
Previously Untreated
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
74%
Chemotherapy
61%
Small Cell Lung Cancer
44%
Solid Malignant Neoplasm
37%
Carboplatin
36%
Lung Cancer
35%
Docetaxel
32%
Disease
31%
Phase II Trials
31%
Maximum Tolerated Dose
28%
Paclitaxel
27%
Temsirolimus
23%
Irinotecan
23%
Erlotinib
23%
Epidermal Growth Factor Receptor
23%
Malignant Neoplasm
20%
Adverse Event
20%
Progression Free Survival
20%
Clinical Trial
19%
Overall Survival
15%
Carfilzomib
15%
Sunitinib
15%
Bexarotene
15%
Doxorubicin
15%
Placebo
15%
Nausea and Vomiting
12%
Neoplasm
12%
Neutropenia
12%
Thrombocytopenia
9%
Bevacizumab
9%
Phase I Trials
9%
Prostate Cancer
8%
Brain Metastasis
8%
Etoposide
8%
Cisplatin
8%
Diarrhea
7%
Randomized Clinical Trial
7%
Alisertib
7%
Chemotherapy Induced Nausea and Vomiting
7%
Everolimus
7%
Seribantumab
7%
Estramustine
7%
Sulindac Sulfone
7%
Proteasome Inhibitor
7%
Pemetrexed
7%
Immune Checkpoint Inhibitor
7%
Topotecan
7%
Vasculotropin
7%
Gossypol
7%
Rosiglitazone
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
77%
Chemotherapy
52%
Small Cell Lung Cancer
40%
Lung Cancer
23%
Overall Survival
22%
Carboplatin
21%
Malignant Neoplasm
21%
Phase II Trials
17%
Irinotecan
16%
Medicine
15%
Cancer
15%
Adjuvant Chemotherapy
15%
Carfilzomib
15%
Placebo
15%
Disease
14%
Paclitaxel
13%
Neoplasm
12%
Radiation Therapy
12%
Adverse Event
12%
Non-Small Cell Lung Cancer
11%
Leukemia
10%
Surveillance, Epidemiology, and End Results
9%
Epidermal Growth Factor Receptor
9%
Docetaxel
9%
Base
8%
Next Generation Sequencing
8%
Brain Metastasis
8%
Etoposide
8%
Progression Free Survival
8%
Proton Therapy
7%
Prevalence
7%
Everolimus
7%
Internal Medicine
7%
Sunitinib
7%
Celecoxib
7%
Cyclooxygenase 2
7%
Erlotinib
7%
Attributable Risk
7%
Prostate Cancer
7%
Sulindac Sulfone
7%
Prostatectomy
7%
Chemotherapy Agent
7%
Estramustine
7%
Clinical Oncology
7%
Treatment Duration
7%
Chemoradiotherapy
7%
Gossypol
7%
Proteasome Inhibitor
7%
Meta-Analysis
7%
Olaratumab
7%